Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 22.46% | -77.56% | |||
| Gross Profit | -22.46% | 77.56% | |||
| SG&A Expenses | 10.29% | 0.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.47% | 31.23% | |||
| Operating Income | -16.47% | -31.23% | |||
| Income Before Tax | -27.96% | -35.73% | |||
| Income Tax Expenses | 40.50% | -80.09% | |||
| Earnings from Continuing Operations | -28.23% | -20.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.23% | -20.22% | |||
| EBIT | -16.47% | -31.23% | |||
| EBITDA | -16.52% | -31.31% | |||
| EPS Basic | -21.28% | -16.10% | |||
| Normalized Basic EPS | -21.04% | -31.11% | |||
| EPS Diluted | -21.28% | -16.10% | |||
| Normalized Diluted EPS | -21.04% | -31.11% | |||
| Average Basic Shares Outstanding | 5.77% | 3.54% | |||
| Average Diluted Shares Outstanding | 5.77% | 3.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||